cTAP to Present at Annual Biopharmaceutical Conference

Published June 25, 2018

The collaborative Trajectory Analysis Program (cTAP), a multi-stakeholder, pre-competitive global coalition in Duchenne muscular dystrophy today announced that Susan J. Ward, Ph.D., Executive Director of cTAP, will present at the 2018 ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop Annual Conference in Washington DC on Thursday, September 13, 2018 at 1:15 p.m. EST.

Debra Miller, CEO of CureDuchenne, a patient foundation in Duchenne that provided seed funding for cTAP and is a founding advocacy partner, said: “cTAP has built a strong collaborative analytics platform through which drug developers have a forum to harness their shared experience in problem solving; it’s great to see the conference organizers provide an opportunity for drug developers in rare disease to learn more about the cTAP model.”

The presentation slide deck will be available after the conference.

About cTAP

About cTAP Driven by a shared mission to overcome the challenges of developing drugs for diseases characterized by heterogeneous progression, like Duchenne muscular dystrophy (DMD), cTAP brings advanced data science to a dynamic alliance of all stakeholders in the ecosystem through a partnership with outcomes research experts at Analysis Group Inc. cTAP has secured access to a large and growing natural history database of clinical patient data in DMD. By combining this rich resource with a uniquely collaborative and pan-stakeholder analysis platform, cTAP develops solutions with the urgency necessary to enhance clinical trial design and analysis, near-term.

About Analysis Group

With more than 800 professionals, many with advanced degrees and expertise in health outcomes research, epidemiology, strategy, biostatistics, economics, and other quantitative disciplines, Analysis Group has established a leadership role in the science, economics, and business strategy of the global health care industry. The firm’s offices are located nationally in Boston, Chicago, Dallas, Denver, Los Angeles, Menlo Park, New York, San Francisco, and Washington, D.C.; and internationally in Montreal, London, Brussels, Paris and Beijing.

About Duchenne Muscular Dystrophy

Duchenne muscular dystrophy is a uniformly fatal, progressive muscle-wasting disease affecting about one in 3,500-6,000 male live births. Patients with Duchenne lack the ability to make dystrophin, a protein crucial to muscle function. As their muscles deteriorate, they progressively lose the ability to walk, feed themselves, turn over in bed, and ultimately to breathe. While there is no cure, the past decade has seen an explosion in research resulting in more than 15 therapies entering clinical development, with some receiving limited approval. Learn more about Duchenne at cureduchenne.org, parentprojectmd.org and charleysfund.org.